241 related articles for article (PubMed ID: 32650561)
21. What is the real impairment on esophageal motility in patients with gastroesophageal reflux disease?
Falcão A; Nasi A; Brandão J; Sallum R; Cecconello I
Arq Gastroenterol; 2013 Apr; 50(2):111-6. PubMed ID: 23903620
[TBL] [Abstract][Full Text] [Related]
22. Sex and Gender Differences in Gastroesophageal Reflux Disease.
Kim YS; Kim N; Kim GH
J Neurogastroenterol Motil; 2016 Oct; 22(4):575-588. PubMed ID: 27703114
[TBL] [Abstract][Full Text] [Related]
23. Relevance of ineffective esophageal motility and hyperactive acid sensitization in patients with gastroesophageal reflux.
Hong SJ; Ko BM; Jung IS; Ryu CB; Moon JH; Cho JY; Kim JO; Lee JS; Lee MS; Shim CS; Kim BS
J Gastroenterol Hepatol; 2007 Oct; 22(10):1662-5. PubMed ID: 17559356
[TBL] [Abstract][Full Text] [Related]
24. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
[TBL] [Abstract][Full Text] [Related]
25. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenocarcinoma.
Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):727-31. PubMed ID: 18349295
[TBL] [Abstract][Full Text] [Related]
26. Comparison of esophageal acid exposure distribution along the esophagus among the different gastroesophageal reflux disease (GERD) groups.
Dickman R; Bautista JM; Wong WM; Bhatt R; Beeler JN; Malagon I; Risner-Adler S; Lam KF; Fass R
Am J Gastroenterol; 2006 Nov; 101(11):2463-9. PubMed ID: 17090277
[TBL] [Abstract][Full Text] [Related]
27. No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study.
Ferguson HR; Wild CP; Anderson LA; Murphy SJ; Johnston BT; Murray LJ; Watson RG; McGuigan J; Reynolds JV; Hardie LJ
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):736-9. PubMed ID: 18349297
[TBL] [Abstract][Full Text] [Related]
28. Precise role of acid in non-erosive reflux disease.
Wang C; Hunt RH
Digestion; 2008; 78 Suppl 1():31-41. PubMed ID: 18832838
[TBL] [Abstract][Full Text] [Related]
29. Prebiotic proanthocyanidins inhibit bile reflux-induced esophageal adenocarcinoma through reshaping the gut microbiome and esophageal metabolome.
Weh KM; Howard CL; Zhang Y; Tripp BA; Clarke JL; Howell AB; Rubenstein JH; Abrams JA; Westerhoff M; Kresty LA
JCI Insight; 2024 Feb; 9(6):. PubMed ID: 38329812
[TBL] [Abstract][Full Text] [Related]
30. Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.
Samuels T; Hoekzema C; Gould J; Goldblatt M; Frelich M; Bosler M; Lee SH; Johnston N
Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):893-902. PubMed ID: 26077392
[TBL] [Abstract][Full Text] [Related]
31. [Diagnostic values of GerdQ, 24-h ambulatory oesophageal pH and impedance-pH monitoring in Barrett's esophagus, reflux esophagitis and non-erosive reflux disease].
Wang K; Duan LP; Ge Y; Xu ZJ; Xia ZW
Zhonghua Yi Xue Za Zhi; 2011 May; 91(18):1228-32. PubMed ID: 21756791
[TBL] [Abstract][Full Text] [Related]
32. Reflux injury of esophageal mucosa: experimental studies in animal models of esophagitis, Barrett's esophagus and esophageal adenocarcinoma.
Li Y; Martin RC
Dis Esophagus; 2007; 20(5):372-8. PubMed ID: 17760649
[TBL] [Abstract][Full Text] [Related]
33. The impact of antireflux surgery on oxidative stress of esophageal mucosa caused by gastroesophageal reflux disease: 4-yr follow-up study.
Rantanen TK; Räsänen JV; Sihvo EI; Ahotupa MO; Färkkilä MA; Salo JA
Am J Gastroenterol; 2006 Feb; 101(2):222-8. PubMed ID: 16454822
[TBL] [Abstract][Full Text] [Related]
34. Proteomic screening of a cell line model of esophageal carcinogenesis identifies cathepsin D and aldo-keto reductase 1C2 and 1B10 dysregulation in Barrett's esophagus and esophageal adenocarcinoma.
Breton J; Gage MC; Hay AW; Keen JN; Wild CP; Donnellan C; Findlay JB; Hardie LJ
J Proteome Res; 2008 May; 7(5):1953-62. PubMed ID: 18396902
[TBL] [Abstract][Full Text] [Related]
35. Associations of microbiota and toll-like receptor signaling pathway in esophageal adenocarcinoma.
Zaidi AH; Kelly LA; Kreft RE; Barlek M; Omstead AN; Matsui D; Boyd NH; Gazarik KE; Heit MI; Nistico L; Kasi PM; Spirk TL; Byers B; Lloyd EJ; Landreneau RJ; Jobe BA
BMC Cancer; 2016 Feb; 16():52. PubMed ID: 26841926
[TBL] [Abstract][Full Text] [Related]
36. From Reflux Esophagitis to Esophageal Adenocarcinoma.
Souza RF
Dig Dis; 2016; 34(5):483-90. PubMed ID: 27331918
[TBL] [Abstract][Full Text] [Related]
37. Esophageal mucosal eicosanoids in gastroesophageal reflux disease and Barrett's esophagus.
Triadafilopoulos G; Kaczynska M; Iwane M
Am J Gastroenterol; 1996 Jan; 91(1):65-74. PubMed ID: 8561146
[TBL] [Abstract][Full Text] [Related]
38. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
39. Three clinical variants of gastroesophageal reflux disease form two distinct gene expression signatures.
Ostrowski J; Rubel T; Wyrwicz LS; Mikula M; Bielasik A; Butruk E; Regula J
J Mol Med (Berl); 2006 Oct; 84(10):872-82. PubMed ID: 16924468
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of erosive esophagitis and Barrett's esophagus in the adult Chinese population.
Peng S; Cui Y; Xiao YL; Xiong LS; Hu PJ; Li CJ; Chen MH
Endoscopy; 2009 Dec; 41(12):1011-7. PubMed ID: 19967617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
